Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taxol Adjuvant Indication Should Refer To Receptor Status Effect On Efficacy

Executive Summary

The indication for Bristol-Myers Squibb's Taxol should refer physicians to the "clinical studies" section of labeling for information about receptor subgroup analyses, FDA's Oncologic Drugs Advisory Committee said Sept. 17 in recommending sequential administration of Taxol (paclitaxel) following chemotherapy for node-positive breast cancer.

You may also be interested in...

Taxol Adjuvant Benefit In Receptor-Positive Breast Cancer Not Yet Clear

Bristol-Myers Squibb's Taxol (paclitaxel) approval for sequential adjuvant therapy allows for use of the drug in estrogen and progesterone receptor-negative and positive tumors, although no benefit has been made clear in the receptor-positive group.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts